Followers | 20 |
Posts | 1722 |
Boards Moderated | 0 |
Alias Born | 11/17/2009 |
Tuesday, December 09, 2014 11:32:52 PM
Nanologix represents less than 1% of the companies competing for market share of Group B Strep but the above analysis assumes they'll capture 20% of the total Group B Strep market? That is highly illogical in my opinion especially since they haven't even captured a percent of the market thusfar and the product hasn't even been approved for commercial use. The poorly thought out analysis has counted the chickens before they've hatched.
My analysis isn't based on assumptions, nor highly illogical ones. It is based on what is actually occurring and what has occurred.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM